Mavyret/Maviret is a combination of glecaprevir and pibrentasvir and is used as a pan-genotypic DAA regimen for hepatitis C. Regimen selection still depends on cirrhosis status, prior treatment history, and drug interactions. Duration and monitoring are individualized. Adherence is critical, and therapy should not be started without a proper interaction review.